BioStock: Curasight’s eventful half-year crowned by EMA approval
It has been an eventful year so far for Curasight. The company has completed a successful rights issue raising DKK 47 million, advanced its phase II prostate cancer trial with uTRACE, and strengthened the strategic investor base. But the most significant milestone came this August: the European Medicines Agency (EMA) approved the company’s clinical trial application for uTREAT, paving the way for its first therapeutic study in brain cancer.
Read the full article at biostock.se:
Curasight's eventful six months were crowned by EMA approval
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/